Human Genome Research

Active

Assistance listing
93.172
Agency
Grant awards
4,729 $11,034,366,990 in federal obligations

Program facts

Also known as
National Human Genome Research Institute
Assistance types
  • Project Grant
  • Cooperative Agreement
  • Block Grant
Treasury account
  • 75-0891-0-1-552
More information

Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.

About this program

The National Human Genome Research Institute (NHGRI), a component of the Department of Health and Human Services National Institutes of Health, funds basic and applied research in genomic science, functional genomics, genomic computational and data science, workforce development, and the ethical, legal, and social implications of genomics through the Human Genome Research program, CFDA 93.172, with the most recent grant award disbursed on February 10, 2027.

The program funds a broad portfolio of activities: basic genomics research investigating gene function and regulation; functional genomics studies including single-cell and spatial transcriptomics, epigenetics, and chromatin organization; genomic data science and computational methods for variant interpretation and disease mechanism discovery; development of genomic resources and technologies applicable across biomedical research; genomic approaches to clinical medicine including rare disease diagnosis, pharmacogenomics, and population screening; and research on the ethical, legal, and social implications of genomic research and clinical implementation. Recent awards exemplify this scope: a study of HSP90-buffered genetic variation to improve variant interpretation and clinical pathogenicity classification; development of machine learning models for cancer risk prediction and rare variant classification; frameworks for population genomic screening in primary care; creation of the Mondo knowledgebase for standardized computational disease definitions; and infrastructure projects like the zebrafish model organism database and AnVIL cloud platform for genomic data sharing and analysis.

The program is predominantly supported by the National Human Genome Research Institute itself, which obligated $7.18 billion federal dollars across 1,693 awards, alongside $2.86 billion obligated by the broader NIH (2,909 awards), the HHS general office ($582.3 million), and smaller contributions from the NIH Office of the Director, the National Cancer Institute, and the National Heart, Lung, and Blood Institute. The assistance-type mix is predominantly Project Grants (87% of 4,133 awards), with smaller shares of Cooperative Agreements (9%, 425 awards) and Block Grants (4%, 171 awards). Combined federal and non-federal obligations total $11.49 billion across 4,729 awards since 1986.

Recent award magnitudes range widely: individual fellowships and early-career awards in the $38,000–$100,000 range; mid-scale project grants in the $200,000–$800,000 range; and larger collaborative or infrastructure awards reaching $2–$5 million or higher. Representative recent awards include a study of epigenetic foundations of transcriptional states ($100,228, National Human Genome Research Institute); the Florida International University Center for Genome Research, a five-year cooperative agreement ($2.5 million); a novel spatial multi-omics platform project ($2.7 million); and a long-read sequencing resource for the 1000 Genomes Project ($620 thousand, cooperative agreement). Workforce development grants support genomic training for nurse scientists, precision medicine fellows, and spatial transcriptomics educators; implementation science initiatives are expanding genomic medicine into primary care across diverse settings.

Award activity has been sustained and recent: 172 awards in 2023, 156 in 2024, 80 in 2025, 69 in 2026, and 3 in early 2027 (as of February). Grant cycle timelines vary: individual and project grants typically move from submission to award in approximately 9 months; SBIR/STTR and AIDS-focused projects in roughly 6 months.

Several grant opportunities are currently open or forecasted: the Investigator-Focused Award (R35) supporting investigator-driven research with funding stability (posted July 30, 2026); the CIDR High Throughput Sequencing and Genotyping Resource Access (X01, posted June 9, 2026); ELSI research on genomics (PAR-28-028, posted June 3, 2026); the AnVIL cloud platform renewal (limited competition U54, posted June 2, 2026); ancient DNA for modern genomics research projects (U01, posted June 2, 2026); and numerous forecasted opportunities including Centers of Excellence in Genomic Science (CEGS), Centers for Genomics Research Capacity Building, and a Clinical Data Ecosystem for Genomics (CDEG) network. R25 education programs support courses, curriculum development, mentoring networks, and research experiences across diverse institutional settings and career stages. Small business innovation and technology transfer programs (SBIR R43/R44, STTR R41/R42) are available for early-stage entrepreneurs commercializing genomic technologies.

Objective and description

Objective

As a leading authority in the field of genomics, the mission of the National Human Genome Research Institute (NHGRI) is to accelerate scientific and medical breakthroughs that improve human health by driving cutting-edge research, developing new tech

Description

The National Human Genome Research Institute supports: (1) the training and career development of the genomics workforce; (2) the development of genomic resources, technologies, and methods in basic genomics, functional genomics, and genomic computational and data science research that are generally applicable to biomedical research; (3) efforts to advance the application of genomics to medical science and clinical care; and (3) studies to understand the ethical, legal, social implications of genomics research for individuals and populations.

Eligibility

Applicant eligibility

Awards can be made to any public or private, for-profit or nonprofit university; college; medical, dental, nursing school; school of public health; hospital; laboratory; or other institution; state and local health departments; other public or private institutions, both for-profit and non-profit; and/or to individuals. National Research Service Award, Institutional Awards: Non-federal public and private domestic organizations may apply. All awardees must be citizens or have been admitted to the United States for permanent residence. Predoctoral awardees must have completed the baccalaureate degree, and postdoctoral awardees must have a professional or scientific degree (M.D., Ph.D., D.O., D.V.M., Sc.D., E.Eng., or equivalent domestic or foreign degree). National Research Service Award. Individual Awardees must be nominated and sponsored by a public or nonprofit private institution having staff and facilities appropriate to the proposed research training program. The applicant's academic record, research experience, citizenship, and institution sponsorship should be documented in the application. All awardees must be citizens or have been admitted to the United States for permanent residence. Predoctoral awardees must have completed the baccalaureate degree, and postdoctoral awardees must have a professional or scientific degree (M.D., Ph.D., D.O., D.V.M., Sc.D., E.Eng., or equivalent domestic or foreign degree). Universities, colleges, medical, dental and nursing schools, schools of public health, laboratories, hospitals, State and local health departments, other public or private institutions, both nonprofit and for-profit, and/or individuals. SBIR/SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees). Primary employment (more than one- half time) of the principal investigator must be with the small business Designations State (includes District of Columbia, public institutions of higher education and hospitals), Local (includes State-designated lndian Tribes, excludes institutions of higher education and hospitals, Public nonprofit institution/organization (includes institutions of higher education and hospitals), Individual/Family, Private nonprofit institution/organization (includes institutions of higher education and hospitals) at the time of award and during the conduct of the proposed project. Small Business Innovation Research (SBIR) Program: SBIR Phase I grants (of approximately 6 months' duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of research initiated in Phase I and which are likely to result in commercial products or processes. Only Phase I awardees are eligible to apply for Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of Phase II application. In both Phase I and Phase II, the research must be performed in the U.S. or its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concerns (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. Any additional eligibility requirements are described at the NOFO level.

Beneficiary eligibility

Any nonprofit or for-profit organization, company, or institution engaged in biomedical research can apply for research support.

Uses of assistance

Grants are awarded to an eligible institution in the name of a principal investigator for a discrete project or group of related projects representing the investigator's interest and competence. Funds may be used for salaries and wages, equipment, supplies, travel and other allowable costs required to carry out the research project. Awardees agree to administer awards in accordance with the regulations and policies governing research assistance programs in the Public Health Service Act, as stated in the NIH Grants Policy Statement and the terms and conditions in the notice of award. Institutional Training Grants are awarded to an eligible institution in the name of a principal investigator for a discrete project or group of related projects representing the investigator's interest and competence. Funds may be used for salaries and wages, equipment, supplies, travel and other allowable costs required to carry out the research project. Awardees agree to administer awards in accordance with the regulations and policies governing research assistance programs in the Public Health Service Act, as stated in the NIH Grants Policy Statement and the terms and conditions in the notice of award. National Research Service Awards institutional training grants may be made to institutions to enable them to select individuals for National Research Service Awards. Each individual who receives a National Research Service Award is responsible for certain service and payback provisions. Individual Training Awards: National Research Service Awards are made directly to individuals for research training in disciplines supporting the research areas. Each individual who receives a National Research Service Award is responsible for certain service and payback provisions. Funds may be used for salaries and wages, equipment, supplies, travel and other costs required to carry out the research project. Awardees agree to administer awards in accordance with the regulations and policies governing research assistance programs in the Public Health Service Act, as stated in the NIH Grants Policy Statement and terms and conditions in the notice of award. Small Business Innovation Research (SBIR) Program: SBIR Phase I grants (of approximately 6 months' duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of research initiated in Phase I and which are likely to result in commercial products or processes. Only Phase I awardees are eligible to apply for Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of Phase II application. Any additional information is described at the NOFO level.

Use restrictions

Awardees agree to administer awards in accordance with the regulations and policies governing research assistance programs in the Public Health Service Act, as stated in NIH Grants Policy Statement and the terms and conditions, in the notice of award. National Research Service Awards are made directly to individuals for research training in disciplines supporting the research areas. Each individual who receives a National Research Service Award is responsible for certain service and payback provisions. Awardees agree to administer awards in accordance with the regulations and policies governing research assistance programs in the Public Health Service Act, as stated in the terms and conditions in the NIH Grants Policy Statement and in the notice of award. Any additional information is described at the NOFO level.

Length and time phasing of assistance

Research and program projects are awarded for 2-5 years. Institutional training grants are awarded for 5 years. Individual fellowships and career development awards are from 2-5 years. For SBIR and STTR applications, normally Phase I awards are for 6 months and Phase II awards are or 2 years.

How to apply

Criteria for selecting proposals

Criteria for selecting proposals is described at the NOFO level.

Award procedure

Only applications submitted in response to a Notice of Funding Opportunity (NOFO) will be considered for funding. Each application is scientifically reviewed by subject matter experts, with competing applications going through initial peer review and secondary review by an advisory council. All scored applications compete for available funds on the basis of scientific and technical merit, program relevance, program balance among aras of research, and availability of funds. Awards are issued throughout the year by the National Human Genome Research Institute (NHGRI).

Deadlines

Requests for Applications and Program Announcements for Special Review or Set Aside are not necessarily submitted on standard due dates. The submission dates of these funding opportunity announcements can be found at: https://grants.nih.gov/funding/nih-guide-for-grants-and-contracts

Time to approval or disapproval

From submission to award of funds: Individual, project and institutional grants about 9 months; SBIR/STTR and AIDS projects about 6 months.

Renewals

Renewal applications are competitively awarded. The applicant must submit an application in response to a NOFO. The application must undergo scientific and technical merit review and must be considered by a national advisory council before an award is made.

Appeals

The NIH Grants Policy Statement describes appeals: https://grants.nih.gov/policy-and-compliance/nihgps Appeals of initial scientific review are described here: https://grants.nih.gov/grants/policy/nihgps/html5/section_2/2.4.2_appeals_of_initial_scientific_review.htm

Grant opportunities

Opportunity Status Posted Applications due
Investigator-Focused Award (Parent R35) PAR-28-037 Forecasted —
Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed) PAR-27-119 Past —
Research on the Ethical, Legal and Social Implications (ELSI) of Genomics PAR-28-028 Forecasted —
Limited Competition: The NHGRI Analysis, Visualization, and Informatics Lab-space (AnVIL) (U54 Clinical Trial Not Allowed) RFA-HG-28-005 Forecasted —
ancient DNA for Modern Genomics (aDMG) Research Projects (U01 Clinical Trials Not Allowed) RFA-HG-28-003 Forecasted —
Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) PAR-27-040 Forecasted —
Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) PAR-27-039 Forecasted —
Collaborative Program Grant for Interdisciplinary Teams (RM1 Clinical Trial Optional) PAR-27-003 Open
NIH Research Program Projects (Parent P01 Clinical Trial Optional) PA-27-061 Open
Genomic Community Resources (U24 Clinical Trials Not Allowed) RFA-HG-26-002 Forecasted —
NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional) PA-26-002 Open
NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed) PA-27-036 Open
NIH Research Educational Program - Mentoring Activities & Networks (Parent R25/UE5 - Clinical Trial Not Allowed) PA-27-035 Open
Toolkits for Dissemination of Genomic Technologies PAR-26-037 Past —
Centers of Excellence in Genomic Science (CEGS) PAR-26-036 Past —
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-26-001 Open
Limited Competition: Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed) PAR-27-067 Open
Centers for Genomics Research Capacity Building FOR-HG-26-001 Past —
Clinical Data Ecosystem for Genomics (CDEG) FOR-HG-26-005 Past —
ancient DNA for Modern Genomics (aDMG) Coordination Center FOR-HG-26-004 Past —
ancient DNA for Modern Genomics (aDMG) Data Generation and Resource Center FOR-HG-26-003 Past —
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) PA-27-100 Open
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) PA-27-102 Open
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required) PAR-27-078 Open
Forecast to Publish a Notice of Funding Opportunity for Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed) FOR-CA-25-087 Past —
NIH Research Education Program - Courses, Curriculum & Methods (Parent R25 - Clinical Trial Not Allowed) PA-27-034 Open
Predoctoral to Postdoctoral Transition Award (Parent F99/K00 - Clinical Trial Not Allowed) PA-27-037 Open
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional) PAR-27-098 Open
GREGoRi Innovation Projects (U01 Clinical Trial Optional) RFA-HG-27-013 Open
Limited Competition: Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network - Clinical Sites (U01, Clinical Trial Required) RFA-HG-25-012 Closed
Single Source: Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network - Coordinating Center (U01 Clinical Trial Required) RFA-HG-26-008 Closed
GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed) RFA-HG-27-011 Open
GREGoRi Technology Integration Center (U01, Clinical Trials Optional) RFA-HG-27-012 Open
Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed) RFA-HG-27-010 Open
Genomic Variant Interactions With Other Variants Or The Environment (UM1 Clinical Trials Not Allowed) RFA-HG-27-009 Open
NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed) PAR-27-077 Open
Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed) PAR-25-415 Open
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) PAR-25-322 Open
Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed) RFA-HG-27-007 Open
IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed) RFA-HG-27-008 Open
Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed) PAR-25-414 Open
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) PA-25-422 Open
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) PA-25-423 Open
Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional) PAR-25-438 Closed
Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) PAR-25-371 Open
Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) PAR-25-369 Open
Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) PAR-25-370 Open
Enabling Discovery through GEnomics 21-546 Closed
Small Grants for New Investigators to Broaden Participation in Health-Related Research (R21 Clinical Trial Optional) PAR-25-097 Closed
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) PA-25-302 Open
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

Grant awards

Award Recipient Federal obligations Awarded
A functional multi-omics approach to identify HSP90-buffered genetic variation F31HG015198 The Univeristy Of Texas M.d. Anderson Cancer Center $38,283
Exploring epigenetic foundations of complex transcriptional states F31HG014410 Weill Medical College Of Cornell University $100,228
Developing novel probabilistic models to identify causal contributors to disease. F31HG015202 Regents Of The University Of Michigan $40,241
A framework to characterize monogenic disease in founder populations using biobank-scale data F32HG014400 Icahn School Of Medicine At Mount Sinai $76,300
Increasing the throughput of variant classification with multiplexed prime editing and single cell long-read… F31HG014981 Northwestern University $100,228
FIU-center for genome research (FIU-CGR). - florida international university (FIU) is a major public research… UH3HG013615 Florida International University $2,499,947
Hierarchical in vivo assembly for rapid and high-throughput construction of long DNA sequences R44HG014736 Bacstitch DNA Inc. $1,077,022
Reliable detection of robertsonian translocations via genomic proximity mapping R43HG014985 Cytoterra Inc. $296,543
Unbiased amplification of single stranded DNA oligos across versatile application spaces R41HG015248 Dnali Data Technologies, Inc. $484,634
African society of human geneticsmeeting - the african society of human genetics (afshg) was formed in 2003 to foster… R13HG014114 Case Western Reserve University $67,101

Latest 10 of 4,729 listed here. See the rest on GovTribe.

Top recipients by federal obligations

Rank Recipient Federal obligations Share
1 The Broad Institute, Inc. $842,809,282 8%
2 The Leland Stanford Junior University $714,591,262 6%
3 University Of Washington $467,689,047 4%
4 Baylor College Of Medicine $458,873,024 4%
5 The Washington University $368,877,284 3%
6 Jackson Laboratory $299,439,659 3%
7 The Johns Hopkins University $287,682,682 3%
8 University Of North Carolina At Chapel Hill $243,345,766 2%
9 University Of California Santa Cruz $229,538,761 2%
10 Vanderbilt University Medical Center $190,311,931 2%

10 of 533 recipients listed here. See the rest on GovTribe.

Federal obligations by fiscal year

Fiscal year Federal obligations
FY2026 $447,984,960
FY2025 $665,706,871
FY2024 $880,377,355
FY2023 $1,056,684,960
FY2022 $980,896,584
FY2021 $850,716,728
FY2020 $433,589,324
FY2019 $447,157,825
FY2018 $432,208,263
FY2017 $398,650,026
FY2016 $385,673,767
FY2015 $403,935,408
FY2014 $380,908,160
FY2013 $318,525,008
FY2012 $397,692,585
FY2011 $367,208,108
FY2010 $351,483,624
FY2009 $343,623,637
FY2008 $174,587,319
FY2007 $248,500,078
FY2006 $232,560,006
FY2005 $211,861,105
FY2004 $217,831,038
FY2003 $196,340,221
FY2002 $301,820,009
FY2001 $91,858,174
Show all 26

Quick answers

What is Assistance Listing 93.172?

Assistance Listing 93.172 is Human Genome Research, a federal grant program run by National Institutes of Health (Department of Health and Human Services).

What is the CFDA number for Human Genome Research?

Its CFDA number is 93.172: Assistance Listing numbers were called CFDA numbers before 2018.

How much funding has Assistance Listing 93.172 awarded?

4,729 grant awards under 93.172 have obligated $11,034,366,990 in federal funds to 533 recipients.

Who receives the most funding from 93.172?

The recipients obligated the most under Human Genome Research are The Broad Institute, Inc. ($842,809,282), The Leland Stanford Junior University ($714,591,262) and University Of Washington ($467,689,047).

How much did 93.172 obligate in fiscal year 2025?

Grants under 93.172 obligated $665,706,871 in federal funds in fiscal year 2025.

Are there open grant opportunities under 93.172?

37 of the latest 50 opportunities under 93.172 are open or forecasted. The latest, Investigator-Focused Award (Parent R35), was posted on July 30, 2026.

On GovTribe

See this program's full record

  • Every grant award and opportunity under it
  • Funding by recipient, agency and assistance type
  • Alerts for new opportunities
  • Ask GovTribe AI about this program